Jubilant Life Science surges after USFDA approval for RUBY-FILL

Jubilant Life Sciences’ wholly owned subsidiary Jubilant Pharma has received the US Food and Drug Administration approval for RUBY-FILL, for its New Drug Application (NDA) filing. RUBY-FILL will be used for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

Jubilant Life Sciences would launch the product in the current quarter i.e. Q3FY17. The current estimated US market size of the drug is USD 76 million (Rs 505 crore) and has a potential to grow up to USD 250 million (Rs 1662 crore) annually in the next five years.

According to the company’s management, the company’s nuclear medicine portfolio has been expanded with this new development. The newly formed drug is a testimony to its innovation and capability to launch one of the differentiated and niche pipeline products in Jubilant's specialty business. Jubilant Life Science is expecting to boost revenues and profitability of the company.

The share price of Jubilant Life Sciences increased by 9.99 per cent on the bourses in early trades on October 3 and is trading at Rs 666.2 on intraday basis.